US study suggests that tofacitinib is an efficacious treatment for active rheumatoid arthritis

Results of a Phase III study show that at 6 months, 58.3 percent of patients who had previously not responded to treatment with DMARDs, achieved ACR20 response (a 20 percent improvement in symptoms) when treated with the novel oral Janus kinase inhibitor tofacitinib at 10mg BID compared to 31.2 percent in the placebo group. Significant improvements were also observed in the 5 mg BID dose.

Read the whole article on Science Daily

More from Science Daily